Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group Y polysaccharide-tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal group Y polysaccharide-tetanus toxoid conjugate vaccine (MenY-TT) is a monovalent vaccine candidate developed by Sanofi Pasteur for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroup Y. The vaccine consists of the capsular polysaccharide of serogroup Y covalently linked to a tetanus toxoid carrier protein. This conjugation technology is designed to enhance the immune response by converting the polysaccharide from a T-cell independent to a T-cell dependent antigen. This conversion is particularly important for inducing high-avidity antibodies and immunological memory in infants and young children, who typically respond poorly to plain polysaccharide vaccines. While serogroup Y is a significant cause of meningococcal disease in North America and other regions, Sanofi Pasteur has primarily focused on incorporating this component into its quadrivalent (ACWY) conjugate vaccines, such as MenQuadfi.
- Other names
- Meningococcal serogroup Y conjugate vaccineMenY-TT vaccine
02
Targets
T cell receptor recognizing tetanus toxoid-derived peptidesBCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on meningococcal group Y polysaccharide-tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group Y polysaccharide-tetanus toxoid conjugate vaccine.